.png){kind=icon}
返回
A Practical Guide to Understanding Cost-Effectiveness Analyses
.png){kind=icon}
PRE
AI
DOI：10.1016/j.jaip.2021.10.006.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Cost-effectiveness analysis is a way to understand the value of a health care intervention in terms of assessing the money spent to produce beneficial outcomes. Cost-effectiveness analyses are used by various stakeholders for such purposes because health care resources and financing may be scarce, depending on the economy, and certain interventions may be costly to produce such outcomes compared with other options. These analyses are built on well-researched and robust inputs for costs and outcomes and may be modeled using a technique called Markov chain models, which allow transitions among various health states (eg, alive, dead, outgrow allergy, allergy relapses) relative to the condition of interest to reflect a base-case scenario. Then, the margins of the inputs are explored for a sensitivity analysis of potential findings. These analyses should be investigated from multiple perspectives (eg, society, health care payer). Limitations of the analysis should be clearly stated. Although such models are an informative way to explore a situation and can be performed without additional direct patient intervention, a weakness of the approach is that this may overlook individual patient nuances. Cost-effectiveness analyses are important policy tools to show, on average, an optimal way to improve value in population health. (C) 2021 American Academy of Allergy, Asthma & Immunology
Keyword:
Base case
Cost-effectiveness analysis
Cost-effectiveness threshold
Incremental cost-effectiveness ratio
Markov chain model
Net monetary benefit
Sensitivity analysis
Tornado diagram
Willingness to pay
Quality-adjusted life-years
期刊
IF:
6.6
论文数:
5.3K
被引数:
1.6W
机构
引用论文
Completion of the primary structure of the human type IV collagenase preproenzyme and assignment of the gene (CLG4) to the q21 region of chromosome 16.png)
Genomics
GenomicsIF0
PREAI
分享收藏Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products A Cost-effectiveness AnalysisJAMA NETWORK OPEN
OAAI
JAMA NETWORK OPENIF9.7
OAAI分享收藏EQ-5D: a measure of health status from the EuroQol GroupEQ-5D: EuroQol小组健康状况的衡量标准ANNALS OF MEDICINEOAAI
ANNALS OF MEDICINEIF4.3
OAAI分享收藏
查看更多内容